The Martial-Art Related To PD98059
Baseline characteristics at the registration were as follows: age 72.4?��?46.9?yrs, FVC 2.4?��?0.9?L, % predicted FVC 79.8?��?27.4%, 6-month change in % predicted FVC ?1.7?��?9.3% (range ?42.3�C25.8%), and history of respiratory Carnitine palmitoyltransferase II hospitalization in preceding 6 months 0.2?��?0.4 times (range 0�C2 times). An observational period was 616?��?371 days and 13 patients were dead in this period. In univariate Cox proportional analysis, % predicted FVC, 6-month change in % predicted FVC, and history of respiratory hospitalization in preceding 6 months significantly correlated with survival although age did not. In multivariate analysis, only history of respiratory hospitalization significantly correlated with survival. Conclusion?History of respiratory hospitalization in preceding 6 months is important as a prognostic factor. YOSHINOBU MATSUDA1,2, KAZUNOBU TACHIBANA2, TAROU TAMURA4, KEIKO NAKAO2, YUMIKO SASAKI2, CHIKATOSHI SUGIMOTO2, TORU ARAI2, AKIHIRO TOKORO1, YOSHIKAZU INOUE3 1The Department of Psychosomatic Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan, 2Department of Respiratory Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan, 3Department of Diffuse Lung Diseases and Respiratory Failure, National Hospital Organization click here Kinki-Chuo Chest Medical Center, Osaka, Japan, 4Department of Environmental Health, School of Medicine, University of Fukui, Fukui, Japan Background and Aim of Study?Dyspnea represents a very frequent and distressing PD98059 symptom in patients with terminal stage interstitial pneumonias. The purpose of this study was to assess the efficacy of morphine on the intensity of dyspnea and its effect on respiratory rate in patients with interstitial pneumonia. Methods?We retrospectively assessed data of patients with terminal stage interstitial pneumonias who were referred to palliative care team and received continuous subcutaneous injection of morphine for dyspnea between September 2010 and March 2013. We assessed dyspnea measured on Numerical rating scale (NRS) and respiratory rate before treatment (T0), 2 hours (T2) and 4 hours later (T4). Results?Twenty three patients were assessed. Median dose of morphine was 0.25?mg/h (range 0.125�C0.25?mg/h), 0.25?mg/h (range 0.25�C0.5?mg/h) and 0.25?mg/h (range 0.25�C6.25?mg/h), median NRS was 8 (IQR 5�C10), 6 (IQR 3�C8) and 4 (IQR 3�C7) and median respiratory rate was 36 (IQR 29�C40), 34.5 (IQR 27�C40.5) and 33 (IQR 28�C38) at T0, T2 and T4, respectively. A significant improvement was observed in NRS (T0 versus T2; P?=?0.002, T0 versus T4; P?
